| Date | Name | Symbol | Type | Security | Shares | Price | Value | Ownership | Reported |
| 03/15/2023 | Aligos Therapeutics, Inc. | ALGS | Grant | Stock Option (Right to Buy) | 78.8k | $1.34 | $105.5k | | 03/15/2023 |
| 07/07/2022 | Aligos Therapeutics, Inc. | ALGS | Grant | Stock Option (Right to Buy) | 52.5k | $1.41 | $74k | | 07/07/2022 |
| 02/04/2022 | Aligos Therapeutics, Inc. | ALGS | Grant | Stock Option (Right to Buy) | 105k | $3.06 | $321.3k | | 02/04/2022 |
| 02/04/2022 | Aligos Therapeutics, Inc. | ALGS | Grant | Stock Option (Right to Buy) | 26.2k | $3.06 | $80.3k | | 02/04/2022 |
| 12/01/2020 | Aligos Therapeutics, Inc. | ALGS | Grant | Stock Option (Right to Buy) | 200k | $16.18 | $3.2M | | 12/01/2020 |
| 10/20/2020 | Aligos Therapeutics, Inc. | ALGS | Conversion | Common Stock | 6.8k | $0.00 | $0 | See footnote | 10/20/2020 |
| 10/20/2020 | Aligos Therapeutics, Inc. | ALGS | Conversion | Common Stock | 1.7k | $0.00 | $0 | See footnote | 10/20/2020 |
| 10/20/2020 | Aligos Therapeutics, Inc. | ALGS | Conversion | Common Stock | 726 | $0.00 | $0 | See footnote | 10/20/2020 |
| 10/20/2020 | Aligos Therapeutics, Inc. | ALGS | Conversion | Series A Preferred Stock | 6.8k | $0.00 | $0 | See footnote | 10/20/2020 |
| 10/20/2020 | Aligos Therapeutics, Inc. | ALGS | Conversion | Series B-1 Preferred Stock | 1.7k | $0.00 | $0 | See footnote | 10/20/2020 |
| 10/20/2020 | Aligos Therapeutics, Inc. | ALGS | Conversion | Series B-2 Preferred Stock | 726 | $0.00 | $0 | See footnote | 10/20/2020 |